TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Krishna Inst Of Med Sci L
KIMS

Krishna Inst Of Med Sci L Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 45/100 · Weak See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹780.15

Change

-20.3 (-2.54%)

Open

₹800.95

Prev. Close

₹800.45

Day High

₹801.0

Day Low

₹775.95

Volume Analysis

Traded

346,140

Delivered

192,256

Delivery %

55.54%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (20.0%)

Weaknesses (3)

  • •High debt-to-equity ratio (1.89)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (45/100)

Opportunities (2)

  • •Strong 3-year revenue growth (21.1%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹820.5 ₹810.75 ₹795.45 ₹785.7 ₹770.4 ₹760.65 ₹745.35
Fibonacci ₹810.75 ₹801.18 ₹795.27 ₹785.7 ₹776.13 ₹770.22 ₹760.65
Camarilla ₹787.04 ₹784.74 ₹782.45 ₹785.7 ₹777.85 ₹775.56 ₹773.26

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+26.63%

1 Week

-1.1%

1 Month

+1.19%

3 Months

-4.23%

6 Months

+24.84%

1 Year

+7.36%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹87.32

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

8.04%

Net margin 4.61% × asset turnover 0.51x × equity multiplier 3.42x

Company Overview

Sector

Healthcare

Market Cap

₹32,765 Cr

P/E (TTM)

157.0

ROE

11.3%

Book Value

₹56.2

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.

TopFund Analysis

Krishna Inst Of Med Sci L scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 45/100. The strongest factor is Liquidity (85/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (20.0%); high debt-to-equity ratio (1.89); promoter holding is falling. Strong 3-year revenue growth (21.1%).

TopFund Score — Fundamentals Quality

45/100 — Weak

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

6

Growth

53

Valuation

0

Cash Flow

50

Corporate Governance

30

Momentum

72

Institutional Ownership

76

Business Quality

50

Risk & Volatility

78

Liquidity

85

From Screener.in

  • +Company is expected to give good quarter
  • +Company's median sales growth is 21.9% of last 10 years
  • −Stock is trading at 13.9 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Promoter holding has decreased over last quarter: -1.62%
  • −Company might be capitalizing the interest cost

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 23 Sep 23 Sep
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 15 Sep

Anand Rathi Annual Flagship Conference G-200 Summit 2026 on September 22, 2026 in Mumbai.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 15 Sep

KIMS to attend J.P. Morgan India Conference group meeting in Mumbai on September 21, 2026.

Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements 10 Sep

KIMS signed 5-year renewable O&M agreement for 183-bed Trust Hospitals, Kakinada, earning 9% of net revenue.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 07 Sep

KIMS to meet institutional investors on 10 September 2026 at 2:30 p.m., hosted by Emkay Global.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 606 652 606 634 688 777 772 797 872 961 998 1,075 1,180
Expenses + 449 475 459 475 509 559 585 599 679 757 799 868 956
Operating Profit 157 177 147 159 179 218 187 198 193 204 199 206 223
OPM % 26.0% 27.0% 24.0% 25.0% 26.0% 28.0% 24.0% 25.0% 22.0% 21.0% 20.0% 19.0% 19.0%
Other Income + 3 3 3 4 5 5 18 15 7 4 5 1 17
Interest 9 9 12 16 18 20 26 27 33 45 57 68 83
Depreciation 32 33 35 46 39 41 45 53 53 66 79 85 101
Profit before tax 119 139 102 100 127 162 135 134 114 97 69 55 57
Tax % 27.0% 27.0% 25.0% 28.0% 25.0% 26.0% 31.0% 21.0% 25.0% 26.0% 24.0% 40.0% 34.0%
Net Profit + 87 101 77 72 95 121 92 106 85 72 52 33 37
EPS in Rs 2 2 2 2 2 3 2 3 2 2 1 1 1
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 512 567 664 918 1,123 1,330 1,651 2,198 2,498 3,035 3,905 4,212
Expenses + 403 450 593 833 872 953 1,126 1,587 1,850 2,242 3,090 3,380
Operating Profit 109 118 71 85 251 377 524 611 648 793 815 833
OPM % 21.0% 21.0% 11.0% 9.0% 22.0% 28.0% 32.0% 28.0% 26.0% 26.0% 21.0% 20.0%
Other Income + 5 3 37 6 5 9 27 41 13 43 17 28
Interest 37 32 88 49 44 37 22 37 55 100 215 253
Depreciation 36 35 40 56 71 70 73 129 147 177 283 331
Profit before tax 41 53 -20 -15 141 279 457 485 460 558 334 277
Tax % 32.0% 37.0% 126.0% 223.0% 18.0% 26.0% 25.0% 25.0% 27.0% 26.0% 28.0% —
Net Profit + 28 33 -46 -49 115 205 344 366 336 415 242 194
EPS in Rs 1 1 -1 -1 3 5 8 8 8 10 6 5
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 193 255 -209 466 524 786 1,307 1,590 1,748 2,058 2,167
Borrowings + 256 280 753 336 369 316 257 678 1,355 2,562 4,253
Other Liabilities + 146 167 359 237 228 253 260 553 636 990 1,190
Total Liabilities 665 774 954 1,114 1,194 1,433 1,904 2,901 3,820 5,689 7,691
Fixed Assets + 515 518 755 863 916 931 1,005 1,766 2,434 3,348 5,710
CWIP 2 64 0 0 2 9 21 477 600 1,214 606
Investments 11 14 0 0 0 0 332 68 157 99 103
Other Assets + 137 177 199 250 276 493 546 590 629 1,028 1,271
Total Assets 665 774 954 1,114 1,194 1,433 1,904 2,901 3,820 5,689 7,691
Equity Capital 70 72 50 74 74 78 80 80 80 80 80

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 95 82 106 134 202 356 324 432 521 582 511
Cash from Investing Activity + -41 -100 -64 -110 -125 -354 -412 -416 -753 -1,116 -1,452
Cash from Financing Activity + -65 24 -39 -27 -44 10 61 20 217 543 940
Net Cash Flow -11 5 3 -3 32 12 -26 36 -15 9 -1
CFO/OP 88 80 192 195 102 104 86 87 102 91 81
Free Cash Flow 61 -18 49 57 150 262 154 -140 -125 -380 -902

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 38.85% → 32.49%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 12.1% 11.67% 11.32% 11.22% 13.03% 13.45% 13.78% 18.68% 18.74% 18.85% 18.82% 18.32%
Promoters 38.85% 38.82% 38.82% 38.82% 38.82% 38.82% 38.82% 34.11% 34.11% 34.11% 34.11% 32.49%
FII 14.24% 15.27% 16.73% 17.84% 15.85% 15.68% 15.44% 15.54% 15.03% 14.33% 14.57% 14.75%
DII 34.8% 34.24% 33.13% 32.12% 32.29% 32.05% 31.95% 31.65% 32.12% 32.72% 32.5% 34.42%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Krishna Inst Of Med Sci L (this stock) 32,765 157.0 13.88 11.3%
Dr. Lal Path Labs Ltd. 32,299 57.4 12.83 22.3%
Sai Life Sciences Limited 33,821 92.0 13.61 15.4%
Wockhardt Limited 36,814 92.3 7.45 6.11%
Neuland Lab Ltd. 28,085 56.4 14.98 21.2%
Piramal Pharma Limited 28,000 — 3.42 -3.83%
Emcure Pharmaceuticals L 37,595 36.5 7.59 20.1%

Which Mutual Funds Hold Krishna Inst Of Med Sci L?

Frequently Asked Questions about Krishna Inst Of Med Sci L

Community Sentiment

What are other investors saying about Krishna Inst Of Med Sci L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.